SCHEMBL6408723

SCHEMBL6408723

CCC(C)CN(C(=O)OCc1ccccc1)C(=O)N(CCCc1ccccc1)C(c1ccc(OC)cc1)S(N)(=O)=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
ACHE P22303 2/20 0.41
ALOX5 P09917 2/20 0.37
MMP3 P08254 5/20 0.36
KMT2A Q03164 3/20 0.36
MEN1 O00255 2/20 0.36
ALDH1A1 P00352 2/20 0.36
MMP1 P03956 4/20 0.35
MMP2 P08253 4/20 0.35
PDE4A P27815 4/20 0.35
PDE4B Q07343 4/20 0.35
PDE4C Q08493 4/20 0.35
PDE4D Q08499 4/20 0.35
AOC3 Q16853 1/20 0.35
CHRM5 P08912 1/20 0.35
CHRM1 P11229 1/20 0.35
CHRM3 P20309 1/20 0.35
BMP1 P13497 1/20 0.35
ATM Q13315 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6407163 0.90 CA1 (0.42) CA1CA2ACHEALOX5MMP3
SCHEMBL6401370 0.80 L3MBTL1 (0.40) ALOX5MMP3KMT2AMEN1ALDH1A1
SCHEMBL7258293 0.79 L3MBTL1 (0.44) ALOX5MMP3KMT2AMEN1ALDH1A1
SCHEMBL6408728 0.78 AR (0.41) CA1CA2ACHEALOX5MMP3
SCHEMBL6401744 0.76 LMNA (0.38) CA1ALOX5
SCHEMBL6403036 0.74 CACNA1H (0.37) CA1CA2ALOX5
SCHEMBL20147826 0.73 ALDH1A1 (0.50) KMT2AALDH1A1ATMHSD17B10
SCHEMBL6403166 0.71 L3MBTL1 (0.39)
SCHEMBL7257821 0.71 L3MBTL1 (0.39)
SCHEMBL6404802 0.70 CASR (0.38) KMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6900237-B2 Sulfonamide compounds as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2005-05-31 US disclosed
US-20030158231-A1 Sulfonamide compounds as protease inhibitors Celera Corporation 2003-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030158231-A1 Sulfonamide compounds as protease inhibitors PRSS1, PRSS3, SPINT2 CA1 228/4885CA2 216/4885ACHE 1348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.